Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome

Journal of Clinical Oncology

Volumn 20, Issue 8, 2002, Pages 2067-2075

  Sosman, Jeffrey A ^a   Unger, Joseph M ^a   Liu, P Y ^a   Flaherty, Lawrence E ^a   Park, Min S ^a   Kempf, Raymond A ^a   Thompson, John A ^a   Terasaki, Paul I ^a   Sondak, Vernon K ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; HLA A28 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA B44 ANTIGEN; HLA B45 ANTIGEN; HLA C ANTIGEN; HLA C3 ANTIGEN; MELACINE; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HLA TYPING; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 0037089672     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.072     Document Type: Article

References (41)

1. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant
2. A new era for cancer immunotherapy based on the genes that encode cancer antigens
3. Active specific immunotherapy for melanoma
4. Melanoma-specific lysis by cloned CD4+ and CD8+ T cells from actively immunized melanoma patients
5. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation
6. MHC ligands and peptide motifs: First listing
7. Definition of specific peptide motifs for four major HLA-A alleles
8. Association of HLA phenotype with response to active specific immunotherapy of melanoma
9. Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine: I. Overall results of a randomized trial of the Southwest Oncology Group
10. Histocompatibility testing
11. The basic lymphocyte microcytotoxicity tests
12. Regression models and life-tables
13. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes: Implications for peptide-based immunotherapy
14. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
15. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
16. HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B 44
17. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes
18. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes
19. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3
20. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
21. The trimmed-haplotype test for linkage disequilibrium
22. HLA gene and haplotype frequencies in the North American population: The National Marrow Donor Program Donor Registry
23. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product
24. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
25. Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens
26. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma
27. Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma
28. HLA-A 2 subtypes are functionally distinct in peptide binding and presentation
29. The role of CD4+ T cell responses in antitumor immunity
30. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
31. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC 27 as a tumor antigen
32. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
33. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A 2 melanomas
34. Two tyrosinase nonapeptides recognized on HLA-A 2 melanomas by autologous cytolytic T lymphocytes
35. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes: Implications for peptide-based immunotherapy
36. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1
37. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw* 1601
38. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy
39. HLA associations in the antitumor response against malignant melanoma
40. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?